Greenland Mines Ltd (GRML) company profile
Close on Nov 20, 2026Market cap $40.92MP/E –Yield –
About Greenland Mines
Biological Products, (No Diagnostic Substances), SIC 2836
Greenland Mines Ltd, previously known as Klotho Neurosciences, Inc., is a biotechnology company focused on developing treatments for chronic illnesses, including neurodegenerative conditions, cancer, and cardiovascular diseases. Its product pipeline centers on proprietary gene and cell therapy candidates, specifically KLTO-101 for Alzheimer's disease and KLTO-202 for amyotrophic lateral sclerosis, which utilize the Klotho protein. Additionally, the company maintains licensed platforms comprising generic pharmaceuticals and biosimilar biologics targeting various solid tumors, and it operates an initiative focused on exploring and mining critical and precious minerals. Its therapeutics target adult and pediatric patient populations suffering from severe chronic disorders.
The company maintains its executive headquarters in Charlotte, North Carolina. Its operational footprint and intellectual property assets span multiple international regions. It holds marketing authorizations for five anti-cancer medications approved for sale in Germany. Furthermore, the organization conducts sponsored scientific research through academic partnerships in Spain and holds patent rights and applications across the United States, Europe, Canada, China, and other global territories.
Summary of the business section of Greenland Mines's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Greenland Mines Ltd
- Headquarters
- Omaha, NE
- Address
- 13576 Walnut Street, Suite A 68144
- Phone
- (833) 931-6330
- Website
- greenlandmines.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- BCRG Group, Irvine, CA
Stock & identifiers
- Ticker
- GRML
- Other tickers
- GRMLW
- Former tickers
- KLTO until Mar 23, 2026; WENA until Oct 2, 2024; RWOD until Jun 27, 2024
- Exchange
- Nasdaq
- IPO date
- Apr 29, 2022
- Shares outstanding
- 159M, Aug 17, 2026
- Public float
- $52.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-49 reverse, Nov 16, 2026; 1-for-50 reverse, Aug 24, 2026
- SEC CIK
- 1907223
- CUSIP
- 49876K111
- ISIN
- US49876K1117
- FIGI
- BBG015Z249H2
- Share class FIGI
- BBG015Z24BT4
- EIN
- 86-2727441
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph Sinkule | Chief Executive Officer, Director | 6,346,700 |
| Jeff LeBlanc | Chief Financial Officer | 110,406 |
| Jason David Sawyer | Director | 240,000 |
| Jon McGarity | Director | 551,277 |
| Samuel M. Zentman | Director | 1,086,440 |
| Shalom Hirschman | Director | 908,873 |
Corporate history
Events identified from SEC filings
See a number that looks wrong?